Antigen binding proteins that bind WISP1
There is disclosed compositions and methods relating to or derived from anti-WISP1 antibodies. More specifically, there is disclosed fully human antibodies that bind WISP1, WISP1-binding fragments and derivatives of such antibodies, and WISP1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having WISP1 related disorders or conditions. There is also disclosed a method for treating or preventing various cancers or inflammatory diseases and various diseases of the heart, bone/joints or lung.
1. An anti-WISP1 antibody or antigen-binding fragment thereof that binds to a WISP1 epitope comprising a heavy chain variable region sequence comprising the CDRs set forth in a first amino acid sequence and a light chain variable region sequence comprising the CDRs set forth in a second amino acid sequence, wherein the first and second amino acid sequences are SEQ ID NO:39 and SEQ ID NO:40; SEQ ID NO:47 and SEQ ID NO:48; SEQ ID NO:53 and SEQ ID NO:54; SEQ ID NO:61 and SEQ ID NO:62; or SEQ ID NO:63 and SEQ ID NO:64, respectively.
2. The anti-WISP1 antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody has a heavy chain/light chain variable region sequence selected from the group consisting of SEQ ID NO:39/SEQ ID NO:40 (called WIr2C11 herein), SEQ ID NO:47/SEQ ID NO:48 (called WIr2D6 herein), SEQ ID NO:53/SEQ ID NO:54 (called WIr2F6 herein), SEQ ID NO:61/SEQ ID NO:62 (called WIr2H3 herein), SEQ ID NO:63/SEQ ID NO:64 (called WIr2H4 herein).
3. A method for treating or preventing a cancer, an inflammatory disease or a disease of the heart, a disease of bone/joints or a lung disease, in a subject, the method comprising, administering an effective amount of the anti-WISP1 antibody or antigen-binding fragment thereof of claim 1 , such that the cancer, the inflammatory disease, the disease of the heart, the disease of bone/joints or the lung disease, is treated.
4. The method of claim 3 , wherein the cancer is selected from the group consisting of hepatocellular carcinoma, colon adenocarcinoma, lung carcinoma, and breast cancer.
5. The method of claim 3 , wherein the inflammatory disease, the disease of the heart, the disease of bone/joints or the lung disease, is selected from the group consisting of: myocardial infarction, angina, osteoarthritis, pulmonary fibrosis, asthma, cystic fibrosis, bronchitis, and asthma.
6. The anti-WISP1 antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody has a K D of at least 1×10 −8 M.
7. A pharmaceutical composition comprising the recombinant fully human anti-WISP1 antibody of claim 1 , and a pharmaceutically acceptable carrier.
8. The anti-WISP1 antibody or antigen-binding fragment thereof of claim 1 , which is a fully human antibody or antigen-binding fragment thereof.
9. The anti-WISP1 antibody or antigen-binding fragment thereof of claim 1 , which is of an IgG class.
10. The anti-WISP1 antibody or antigen-binding fragment thereof of claim 1 , wherein the heavy chain variable region sequence is at least 95% identical to the first sequence and the light chain variable region sequence is at least 95% identical to the second sequence.
11. An anti-WISP1 antibody Fab fragment that binds to a WISP1 epitope, wherein the Fab fragment comprises a variable region from a heavy chain and a variable region from a light chain, wherein the heavy chain variable region sequence comprises the CDRs set forth in a first amino acid sequence, and the light chain variable region sequence comprises the CDRs set forth in a second amino acid Sequence, wherein the first and second amino acid sequences are SEQ ID NO:39 and SEQ ID NO:40; SEQ ID NO:47 and SEQ ID NO:48; SEQ ID NO:53 and SEQ ID NO:54; SEQ ID NO:61 and SEQ ID NO:62; or SEQ ID NO:63 and SEQ ID NO:64, respectively.
12. The anti-WISP1 antibody Fab fragment of claim 11 , wherein the Fab fragment comprises a heavy chain light chain variable region sequence selected from the group consisting of SEQ ID NO:39/SEQ ID NO:40, SEQ ID NO:47/SEQ ID NO:48, SEQ ID NO:53/SEQ ID NO: 54, SEQ ID NO:61/SEQ ID N0:62, SEQ ID NO:63/SEQ ID NO:64.
13. A method for treating or preventing a cancer, an inflammatory disease or a disease of the heart, a disease of bone/joints or a lung disease, in a subject, the method comprising administering an effective amount of the anti-WISP1 antibody Fab fragment of claim 11 , such that the cancer, the inflammatory disease, the disease of the heart, the disease of bone/joints or the lung disease, is treated.
14. The method of claim 13 , wherein the cancer is selected from the group consisting of hepatocellular carcinoma, colon adenocarcinoma, lung carcinoma, and breast cancer.
15. The method of claim 13 , wherein the inflammatory disease, the disease of the heart, the disease of bone/joints or the lung disease is selected from the group consisting of myocardial infarction, angina, osteoarthritis, pulmonary fibrosis, asthma, cystic fibrosis, bronchitis, and asthma.
16. The anti-WISP1 antibody Fab fragment of claim 11 , wherein the antibody Fab fragment has a K D of at least 1×10 −6 M.
17. A pharmaceutical composition comprising the fully human anti-WISP1 antibody Fab fragment of claim 3 , and a pharmaceutically acceptable carrier.
18. The anti-WISP1 antibody Fab fragment of claim 11 , which is a fully human Fab fragment.
19. The anti-WISP1 antibody Fab fragment of claim 11 , wherein the heavy chain variable region sequence is at least 95% identical to the first sequence and the light chain variable region sequence is at least 95% identical to the second sequence.
20. A single chain anti-WISP1 antigen binding fragment that binds to a WISP1 epitope comprising a variable region from a heavy chain and a variable region from a light chain and a peptide linker joining the heavy chain and light chain variable regions, wherein the heavy chain variable region sequence comprises the CDRs set forth in a first amino acid sequence, and the light chain variable region sequence comprises the CDRs set forth in a second amino acid sequence, wherein the first and second amino acid sequences are SEQ ID NO:39 and SEQ ID NO:40; SEQ ID NO:47 and SEQ ID NO:48; SEQ ID NO:53 and SEQ ID NO:54; SEQ ID NO:61 and SEQ ID NO:62; or SEQ ID NO:63 and SEQ ID NO:64, respectively.
21. The single chain antibody of claim 20 , wherein the single chain fully human antibody has a heavy chain/light chain Variable region sequence selected from the group consisting of SEQ ID NO:39/SEQ ID NO:40, SEQ ID NO:47/SEQ ID NO:48, SEQ ID NO:53/SEQ ID NO:54, SEQ ID NO:61/SEQ ID NO:62, SEQ ID NO:63/SEQ ID NO:64.
22. The single chain anti-WISP1 antigen binding fragment of claim 20 , comprising a single chain antibody (scFv).
23. A method for treating or preventing a cancer, an inflammatory disease, a disease of the heart, a disease of bone/joints or a lung disease, in a subject, the method comprising administering an effective amount of the single chain anti-WISP1 antigen binding fragment of claim 20 , such that the cancer, the inflammatory disease, the disease of the heart, the disease of bone/joints or the lung disease, is treated.
24. The method of claim 23 , wherein the cancer is selected from the group consisting of hepatocellular carcinoma, colon adenocarcinoma, lung carcinoma, and breast cancer.
25. The method of claim 23 , wherein the inflammatory disease, the disease of the heart, the disease of bone/joints or the lung disease, is selected from the group consisting of: myocardial infarction, angina, osteoarthritis, pulmonary fibrosis, asthma, cystic fibrosis, bronchitis, and asthma.
26. The single chain anti-WISP1 antigen binding fragment of claim 20 , wherein the antibody Fab fragment has a K D of at least 1×10 −6 M.
27. A pharmaceutical composition comprising the single chain anti-WISP1 antigen-binding fragment of claim 5 , and a pharmaceutically acceptable carrier.
28. The single chain antibody of claim 5 , wherein the heavy chain variable region sequence is at least 95% identical to the first sequence and the light chain variable region sequence is at least 95% identical to the second sequence.